Stockscreener 앱 받기
20.03
6.71%
1.26
시간 외 거래:
20.50
0.47
+2.35%
Zai Lab Limited Adr 주식(ZLAB)의 최신 뉴스
Zai Lab (NASDAQ:ZLAB) Shares Gap UpHere's Why - MarketBeat
Constellation Software Inc. (OTCMKTS:CNSWF) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Analysts Set Kraken Robotics Inc. (CVE:PNG) PT at C$7.13 - Defense World
Brokerages Set Whirlpool Corporation (NYSE:WHR) Target Price at $85.43 - Defense World
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $51.59 Consensus Price Target from Analysts - Defense World
Everus Construction Group, Inc. (NYSE:ECG) Receives $102.75 Average PT from Brokerages - Defense World
FY2026 Earnings Forecast for PACCAR Issued By Zacks Research - Defense World
Plexus Corp. (NASDAQ:PLXS) Receives $189.20 Average Target Price from Analysts - Defense World
Brokerages Set Adherex Technologies Inc. (NASDAQ:FENC) PT at $14.50 - Defense World
Brokerages Set Medical Properties Trust, Inc. (NYSE:MPW) Price Target at $6.17 - Defense World
Zai Lab Limited's (NASDAQ:ZLAB) Shift From Loss To Profit - Yahoo Finance
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
JPMorgan Chase & Co. Has Lowered Expectations for Zai Lab (NASDAQ:ZLAB) Stock Price - MarketBeat
$207B Market Shift: The Race for Fast Track Approval in Oncology - Benzinga
$207B Market Shift: The Race for Fast Track Approval in Oncology - Sahm
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter - Benzinga
Hilton Food Group (LON:HFG) Insider Purchases £198,900 in Stock - Defense World
Zai Lab (NASDAQ:ZLAB) Reaches New 1-Year Low – Time to Sell? - Defense World
Is UBS’s Global-Innovation Framing Rewriting Zai Lab’s (ZLAB) Long-Term Biopharma Platform Narrative? - Sahm
UBS Sees Zai Lab (ZLAB) as a Rising Global Biopharma Platform - Finviz
Zai Lab (NASDAQ:ZLAB) Sets New 12-Month LowHere's Why - MarketBeat
8 High Growth Chinese Stocks To Buy - Insider Monkey
Zai Lab Limited (ZLAB) Stock Analysis: Eyeing a 169% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Zai Lab (NASDAQ:ZLAB) Stock Rating Upgraded by Jefferies Financial Group - MarketBeat
Short Interest in AiRWA Inc. (NASDAQ:YYAI) Rises By 24.6% - Defense World
Short Interest in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Drops By 19.8% - MarketBeat
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Short Interest Update - Defense World
Assessing Zai Lab (NasdaqGM:ZLAB) Valuation After New AUGTYRO Approval And Pipeline Progress - Sahm
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Animalcare Group (LON:ANCR) Stock Passes Below 200-Day Moving Average – Here’s What Happened - Defense World
How Investors May Respond To Zai Lab (ZLAB) Winning Expanded China Approval For AUGTYRO Cancer Therapy - Sahm
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference - Chartmill
UBS gives Zai Lab (ZLAB) a buy rating - MSN
Zai Lab (NASDAQ:ZLAB) Research Coverage Started at UBS Group - Defense World
UBS Gives Zai Lab (ZLAB) a Buy Rating - Insider Monkey
Zai Lab (ZLAB) Is Up 7.9% After First-In-China AUGTYRO Approval Across TRK TKI Settings - Sahm
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors - BioSpace
China clears new AUGTYRO use for adults with NTRK‑positive cancers - Stock Titan
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference - BioSpace
The Truth About Zai Lab Ltd (ADR): Is This Sleeper Stock About To Explode Or Nah? - AD HOC NEWS
Zai Lab (NASDAQ:ZLAB) Insider Rafael Amado Sells 10,787 Shares - Defense World
The Truth About Zai Lab Ltd (ADR): Is This Sleeper Stock About To Explode Or Fade? - AD HOC NEWS
Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts - TechStock²
EBITDA per share of Zai Lab Ltd. Sponsored ADR – MUN:1ZL - TradingView — Track All Markets
Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025 - ts2.tech
FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug - Sahm
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia - Business Wire
1.12%
0.87%
자본화:
|
볼륨(24시간):